三友醫療(688085.SH):控股子公司產品通過創新醫療器械特別審查程序
格隆匯5月14日丨三友醫療(688085.SH)公佈,公司控股子公司蘇州雲合景從新材料科技有限公司(簡稱“雲合景從”)之“表面多孔聚醚醚酮椎間融合器”於近日通過國家藥品監督管理局醫療器械技術審評中心創新醫療器械特別審查程序(受理號:CQTS2500086),表面多孔聚醚醚酮(PEEK)椎間融合器是在聚醚醚酮椎間融合器的基礎上,通過原位多孔熱壓成型的專利技術,在
PEEK
表面直接構建連通多孔結構實現“優勢性能疊加”,成爲目前唯一能同時滿足影像清晰、力學適配與高效骨結合的融合器。
此次該產品進入創新醫療器械特別審查程序,在註冊申報時將獲得優先辦理的權益,可有效縮短產品註冊週期,加快產品的上市速度。該產品如獲批上市,將進一步豐富公司的產品管線,對公司的業務產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.